BioHarvest to Report Q2 2026 Results on Aug. 11
BioHarvest Sciences Inc. plans to report its second quarter 2026 financial results before the market opens on August 11, 2026, and will host a conference call and webcast at 8:00 AM Eastern Time to review results and provide a business update.
Rhea-AI Filing Summary
BioHarvest Sciences Inc. plans to report its second quarter 2026 financial results before the market opens on August 11, 2026, and will host a conference call and webcast at 8:00 AM Eastern Time to review results and provide a business update.
CEO Zaki Rakib, approaching his first 100 days in the role, expects to discuss the company’s 2026 strategy and growth plan. BioHarvest describes itself as a leader in Botanical Synthesis, operating as a CDMO for plant-based compounds and as a developer of proprietary nutraceutical products.
Positive
- None.
Negative
- None.
Key Figures
Earnings release date: August 11, 2026
Earnings call time: 8:00 AM Eastern Time
CEO tenure milestone: first 100 days
3 metrics
Earnings release date
August 11, 2026
Second quarter 2026 financial results to be reported before market opening
Earnings call time
8:00 AM Eastern Time
Conference call and webcast to discuss Q2 2026 results and business update
CEO tenure milestone
first 100 days
CEO Zaki Rakib notes he is approaching his first 100 days in the role
Key Terms
Botanical Synthesis, contract development and manufacturing organization (CDMO), forward-looking statements, management discussion and analysis
4 terms
Botanical Synthesis technical
"BioHarvest is a leader in Botanical Synthesis, leveraging its patented technology platform"
Botanical synthesis is the lab-based creation or replication of plant-derived compounds, either by chemically building the molecules or by using engineered organisms to produce them, like recreating a recipe in a factory instead of harvesting from a garden. For investors it matters because it can lower costs, secure supply, protect patents, and affect regulatory review and market access for products that rely on consistent, scalable plant ingredients.
contract development and manufacturing organization (CDMO) financial
"within two major business verticals; as a contract development and manufacturing organization (CDMO)"
A contract development and manufacturing organization (CDMO) is a company that develops and produces drugs, vaccines or other medical products for other firms, handling steps from formulation and testing to large-scale manufacturing and quality control. Investors care because CDMOs function like outsourced specialized factories and development partners: their revenue grows when many clients need production capacity or development expertise, so their performance signals broader industry demand and is tied to regulatory approvals and client programs.
forward-looking statements regulatory
"Information set forth in this news release might include forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
management discussion and analysis financial
"other than through our regular management discussion and analysis disclosures"
Management discussion and analysis is the section of a company’s regular financial filing where executives explain recent results, the reasons behind them, current challenges and the outlook in plain language. It’s like a CEO’s guided tour of the company’s performance and plans: it helps investors move beyond raw numbers to understand the assumptions, risks and strategy that will affect future profits and value. Investors use it to judge credibility, spot trends and compare management’s explanations across companies.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will BioHarvest Sciences (BHST) report its Q2 2026 financial results?
BioHarvest Sciences (BHST) will report its second quarter 2026 financial results before the market opens on Tuesday, August 11, 2026. The release will be accompanied by a conference call and webcast discussing results, business performance, and strategic priorities for 2026.
What time is the BioHarvest Sciences (BHST) Q2 2026 earnings call and how can it be accessed?
The Q2 2026 earnings call for BioHarvest Sciences (BHST) is scheduled for 8:00 AM Eastern Time on August 11, 2026. It will be accessible via webcast at https://events.q4inc.com/attendee/553034064, with registration recommended at least 10 minutes before the start.
What topics will BioHarvest Sciences (BHST) cover on the August 11, 2026 earnings call?
BioHarvest Sciences (BHST) expects to review Q2 2026 financial results and provide an update on business operations, including insights into its 2026 strategy and growth plan. CEO Zaki Rakib plans to discuss strategic priorities and the opportunities the company sees ahead.
What does BioHarvest Sciences (BHST) describe as its main business focus?
BioHarvest Sciences (BHST) describes itself as a leader in Botanical Synthesis, using a patented platform to grow plant-based compounds without cultivating whole plants. It operates as a CDMO for customers seeking novel plant-based molecules and develops proprietary nutraceutical health and wellness products.
Will a replay of the BioHarvest Sciences (BHST) Q2 2026 earnings webcast be available?
Yes. A recording of the BioHarvest Sciences (BHST) Q2 2026 earnings webcast will be available for replay on the company’s website in the Investor Relations / Events & Presentations section, allowing shareholders and analysts to review the discussion after the live event.
On which exchanges is BioHarvest Sciences (BHST) listed?
BioHarvest Sciences is listed on NASDAQ under the symbol BHST and on the Frankfurt Stock Exchange under the symbol 8MV0. The company positions itself as a leader in Botanical Synthesis and plant-based molecule development across pharmaceutical-adjacent and nutraceutical markets.
Who is the CEO of BioHarvest Sciences (BHST) and what milestone is mentioned?
The CEO of BioHarvest Sciences (BHST) is Zaki Rakib, who notes he is approaching his first 100 days in the role. He plans to use the August 11, 2026 earnings call to share progress updates and additional insight into the company’s 2026 strategy and growth initiatives.
AI-generated analysis. How Rhea-AI works. Not financial advice.
